公开(公告)号：US20200317795A1

公开(公告)日：2020-10-08

申请号：US16753216

申请日：2018-10-03

Applicant: AMGEN INC.

Inventor： Kenneth WALKER

IPC: C07K16/28 ,  C07K14/47 ,  C12N15/63

Abstract: The present invention relates to transthyretin (TTR) fusions useful in the dimerization and tetramerization of antibodies and antibody fragments, such as Fabs. The TTR fusions proteins described herein are particularly useful in increasing antibody avidity and in enhancing antigen clustering. Methods for treating diseases using the fusion proteins of the present invention are described herein.

公开(公告)号：US20160168213A1

公开(公告)日：2016-06-16

申请号：US14908459

申请日：2014-07-31

Applicant: AMGEN INC.

Inventor： Yumei XIONG ,  Yi ZHANG ,  Jackie Z. SHENG ,  Agnes Eva HAMBURGER ,  Murielle VENIANT-ELLISON ,  Grant SHIMAMOTO ,  Xiaoshan MIN ,  Zhulun WANG ,  Jie TANG ,  Gunasekaran KANNAN ,  Marissa MOCK ,  Kenneth WALKER

IPC: C07K14/475

CPC classification number: C07K14/475 ,  C07K2319/30

Abstract: Constructs comprising GDF15, and mutants thereof are provided. In various embodiments the constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.

Abstract translation: 提供了包含GDF15的构建体及其突变体。 在各种实施方案中，包含GDF15及其突变体的构建体可用于治疗或改善代谢紊乱。 在各种实施方案中，代谢疾病或病症是2型糖尿病，肥胖症，血脂异常，升高的葡萄糖水平，升高的胰岛素水平和糖尿病性肾病。